These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37977064)

  • 21. Immunotherapeutic applications of IL-15.
    Croce M; Orengo AM; Azzarone B; Ferrini S
    Immunotherapy; 2012 Sep; 4(9):957-69. PubMed ID: 23046239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
    Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
    J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-21: basic biology and implications for cancer and autoimmunity.
    Spolski R; Leonard WJ
    Annu Rev Immunol; 2008; 26():57-79. PubMed ID: 17953510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer.
    Ramesh R; Ioannides CG; Roth JA; Chada S
    Methods Mol Biol; 2010; 651():241-70. PubMed ID: 20686970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-related interleukins: old validated targets for new anti-cancer drug development.
    Setrerrahmane S; Xu H
    Mol Cancer; 2017 Sep; 16(1):153. PubMed ID: 28927416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling new therapeutic opportunities: cytokines in prostate cancer.
    Chandran E; Meininger L; Karzai F; Madan RA
    Expert Opin Biol Ther; 2022 Oct; 22(10):1233-1243. PubMed ID: 35930001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
    Dhupkar P; Gordon N
    Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy.
    Li MS; Liu Z; Liu JQ; Zhu X; Liu Z; Bai XF
    Immunotherapy; 2015; 7(2):191-200. PubMed ID: 25713993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 21 - its potential role in the therapy of B-cell lymphomas.
    Bhatt S; Sarosiek KA; Lossos IS
    Leuk Lymphoma; 2017 Jan; 58(1):17-29. PubMed ID: 27405876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of IL-21 in solid tumor therapy.
    Eivary SHA; Kheder RK; Najmaldin SK; Kheradmand N; Esmaeili SA; Hajavi J
    Med Oncol; 2023 May; 40(7):191. PubMed ID: 37249661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-33/ST2 as a potential target for tumor immunotherapy.
    Jiang W; Lian J; Yue Y; Zhang Y
    Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Interleukin-34: a key molecule in the tumor microenvironment].
    Kajihara N; Seino KI
    Rinsho Ketsueki; 2021; 62(8):1302-1307. PubMed ID: 34497220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy.
    Zhang W; Zhao Z; Li F
    Mol Immunol; 2022 Apr; 144():58-70. PubMed ID: 35203022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family.
    Soler MF; Abaurrea A; Azcoaga P; Araujo AM; Caffarel MM
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37945321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-32 and its paradoxical role in neoplasia.
    Hough JT; Zhao L; Lequio M; Heslin AJ; Xiao H; Lewis CC; Zhang J; Bai Q; Wakefield MR; Fang Y
    Crit Rev Oncol Hematol; 2023 Jun; 186():104011. PubMed ID: 37105370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.